Date: 2016-06-20
Type of information: Nomination
Compound:
Company: Gyros Protein Technologies (Sweden)
Therapeutic area: Technology - Services
Type agreement: nomination
Action mechanism:
Disease:
Details: * On June 20, 2016, Gyros Protein Technologies, a pioneer in automated nanoliter-scale immunoassays and leading provider of peptide synthesizers and reagents, announced the appointment of Dr. Frank Witney as Chairman of the Board. Dr. Witney’s appointment is a key milestone in Gyros Protein Technologies’ strategy to build upon the Company’s strong market position through ongoing development of innovative products, commercial expansion, and growth via acquisition. David Patteson, prior chairman of Protein Technologie, remains as a Director.
Dr. Witney has over 30 years of experience in leadership and innovation in the life science industry. Most recently he was President and CEO of Affymetrix, which was acquired by Thermo Fisher Scientific in March 2016. Prior to this, Dr. Witney was President and Chief Executive Officer of Dionex, leading to the company’s successful acquisition by Thermo Fisher Scientific in 2011. Earlier executive roles include President and CEO of Panomics, acquired by Affymetrix, and COO at Packard Biosciences, acquired by PerkinElmer, after which he served as President of their Life Sciences Group. Earlier in his career Dr. Witney held a series of positions at Bio-Rad Laboratories, including Group Operations Manager of the Life Science Group, leading efforts to enter rapidly growing markets for proteomic and bioassay technologies.
Dr. Witney holds a doctorate in molecular and cell biology from Indiana University, and was a post-doctoral fellow at the National Institutes of Health. He is also a member of the Board of Directors of Cerus Corporation and Exagen Diagnostics.
Established in March 2016 by the merger of Gyros AB and Protein Technologies, Inc., Gyros Protein Technologies combines Gyros’ microfluidics, systems development and immunoassay expertise with Protein Technologies’ deep knowledge in developing and manufacturing instruments for peptide synthesis. The Company provides customers an unrivaled range of peptide synthesis and bioanalytical tools for biotherapeutics discovery, development and bioprocessing
Both Gyros and Protein Technologies introduced new platforms in 2015. Gyros launched Gyrolab xPlore™, an automated, nanoliter-scale, single CD immunoassay system, while Protein Technologies introduced the Prelude® X which incorporates novel, efficient heating and UV monitoring technology for economical, rapid synthesis of even the most difficult peptides.
Financial terms:
Latest news:
